Ionis, with new FDA nod, hits a ‘commercial inflection point’

Historically seen as a "platform monetization story," according to one analyst, Ionis now has a potential multibillion-dollar ...
STAT

FDA approves Ionis drug that prevents swelling attacks caused by a rare disease

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
Fierce Pharma

Ionis scores transformational FDA label expansion for Tryngolza

After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the ...
Nasdaq

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...
MedCity News

AstraZeneca drops Ionis-partnered heart drug after Phase 2 success isn’t good enough

A genetic medicine from Ionis Pharmaceuticals designed to reduce high levels of cholesterol has achieved the main goal of a Phase 2 study, but the results are short of what partner AstraZeneca hoped ...

Ionis climbs as FDA clears new therapy to lower triglycerides, pancreatitis risk

The U.S. Food and Drug Administration (FDA) approved on Wednesday Ionis Pharmaceuticals, Inc.’s IONS Tryngolza (olezarsen) to ...
STAT

Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...
Yahoo

Biogen, Ionis to discontinue development of experimental ALS drug

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Illustration shows a test tube in front of displayed Biogen logo (Reuters) - Biogen and Ionis Pharmaceuticals said on ...
Reuters

Ionis Pharma's genetic disease drug succeeds in late-stage study

Jan 22 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab said on Monday its experimental drug reduced the occurrence of painful attacks in patients with a rare genetic disease that triggers ...

IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati

U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty ...
Nasdaq

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...
Morningstar

Ionis Earnings: New Drug Launches on Track; Maintaining Our $69 Fair Value Estimate

Narrow-moat Ionis’ third-quarter results are in line with our expectations. We are maintaining our $69 fair value estimate, and we believe the company is ready for its first two independent US drug ...